JP2015510759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510759A5 JP2015510759A5 JP2014561051A JP2014561051A JP2015510759A5 JP 2015510759 A5 JP2015510759 A5 JP 2015510759A5 JP 2014561051 A JP2014561051 A JP 2014561051A JP 2014561051 A JP2014561051 A JP 2014561051A JP 2015510759 A5 JP2015510759 A5 JP 2015510759A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide molecule
- molecule
- seq
- isolated
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 76
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 76
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 76
- 235000001014 amino acid Nutrition 0.000 claims description 75
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 235000018417 cysteine Nutrition 0.000 claims description 18
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 18
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 12
- 235000004279 alanine Nutrition 0.000 claims description 12
- 230000004438 eyesight Effects 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 210000000411 amacrine cell Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 2
- 208000005400 Synovial Cyst Diseases 0.000 claims description 2
- 206010047571 Visual impairment Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000000763 evoking effect Effects 0.000 claims description 2
- 210000002287 horizontal cell Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 108091008695 photoreceptors Proteins 0.000 claims description 2
- 230000036211 photosensitivity Effects 0.000 claims description 2
- 210000003569 retinal bipolar cell Anatomy 0.000 claims description 2
- 210000002508 rod bipolar cell Anatomy 0.000 claims description 2
- 208000029257 vision disease Diseases 0.000 claims description 2
- 210000000857 visual cortex Anatomy 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 230000004393 visual impairment Effects 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 230000016776 visual perception Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 201000007737 Retinal degeneration Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606663P | 2012-03-05 | 2012-03-05 | |
| US61/606,663 | 2012-03-05 | ||
| PCT/US2013/029171 WO2013134295A1 (en) | 2012-03-05 | 2013-03-05 | Identification of channelrhodopsin-2 (chop2) mutations and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018082403A Division JP2018134098A (ja) | 2012-03-05 | 2018-04-23 | チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510759A JP2015510759A (ja) | 2015-04-13 |
| JP2015510759A5 true JP2015510759A5 (https=) | 2016-04-28 |
| JP6395611B2 JP6395611B2 (ja) | 2018-09-26 |
Family
ID=47892055
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561051A Active JP6395611B2 (ja) | 2012-03-05 | 2013-03-05 | チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 |
| JP2018082403A Withdrawn JP2018134098A (ja) | 2012-03-05 | 2018-04-23 | チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 |
| JP2019123061A Pending JP2019193656A (ja) | 2012-03-05 | 2019-07-01 | チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018082403A Withdrawn JP2018134098A (ja) | 2012-03-05 | 2018-04-23 | チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 |
| JP2019123061A Pending JP2019193656A (ja) | 2012-03-05 | 2019-07-01 | チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10947281B2 (https=) |
| EP (1) | EP2822964B1 (https=) |
| JP (3) | JP6395611B2 (https=) |
| KR (1) | KR102137717B1 (https=) |
| CN (2) | CN104334575A (https=) |
| AU (4) | AU2013230112A1 (https=) |
| CA (1) | CA2866405A1 (https=) |
| DK (1) | DK2822964T3 (https=) |
| EA (1) | EA201491643A1 (https=) |
| ES (1) | ES2703324T3 (https=) |
| HU (1) | HUE040487T2 (https=) |
| MX (1) | MX360085B (https=) |
| NZ (1) | NZ629843A (https=) |
| PL (1) | PL2822964T3 (https=) |
| PT (1) | PT2822964T (https=) |
| WO (1) | WO2013134295A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2019588A4 (en) | 2006-05-04 | 2010-11-24 | Univ Wayne State | RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN |
| WO2011140279A1 (en) | 2010-05-04 | 2011-11-10 | Wayne State University | Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
| AU2013230112A1 (en) | 2012-03-05 | 2014-09-25 | Wayne State University | Identification of channelrhodopsin-2 (Chop2) mutations and methods of use |
| US9730888B2 (en) | 2013-03-14 | 2017-08-15 | Wayne State University | Method of enhancing delivery of therapeutic compounds to the eye |
| JP6469669B2 (ja) | 2013-07-08 | 2019-02-13 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | オキシムエステル光開始剤 |
| AU2015229464B2 (en) | 2014-03-11 | 2021-07-22 | Wayne State University | A modified mGluR6 promoter and methods of use |
| RU2018142273A (ru) | 2016-05-03 | 2020-06-03 | Чжо-хуа Пань | Способ улучшения опосредованной вирусами доставки генов в глаз с использованием ингибиторов протеасом |
| WO2017207745A1 (en) * | 2016-06-03 | 2017-12-07 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Mutant light-inducible ion channel of channelrhodopsin |
| CA3034887A1 (en) * | 2016-08-29 | 2018-03-08 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
| WO2018106369A2 (en) * | 2016-11-06 | 2018-06-14 | Nanoscope Technologies Llc | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof |
| EP3609518A1 (en) * | 2017-04-12 | 2020-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | New optogenetic tool |
| SI3720428T1 (sl) * | 2017-12-04 | 2023-05-31 | Laboratorios Salvat, S. A. | Oftalmični lokalni sestavek, ki vsebuje dobesilno kislino za zdravljenje bolezni posteriornega očesnega segmenta |
| JP6567153B1 (ja) * | 2018-09-28 | 2019-08-28 | 学校法人東北工業大学 | 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム |
| WO2024226667A2 (en) * | 2023-04-24 | 2024-10-31 | Nanoscope Therapeutics Inc. | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4498919A (en) | 1983-10-31 | 1985-02-12 | Corning Glass Works | Method for making colored photochromic prescription ophthalmic lenses |
| US6610287B1 (en) | 1990-04-16 | 2003-08-26 | The General Hospital Corporation | Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| US5827702A (en) | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
| CA2287495A1 (en) | 1997-04-21 | 1998-10-29 | University Of Florida | Materials and methods for treatment of retinal diseases |
| WO2000015822A1 (en) | 1998-09-17 | 2000-03-23 | University Of Florida | Methods for treatment of degenerative retinal diseases |
| CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| CA2442670A1 (en) | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| WO2003016486A2 (en) | 2001-08-16 | 2003-02-27 | Sloan Kettering Institute For Cancer Research | Bio-synthetic photostimulators and methods of use |
| DE10216005A1 (de) | 2002-04-11 | 2003-10-30 | Max Planck Gesellschaft | Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle |
| AU2003249318A1 (en) | 2002-07-18 | 2004-02-09 | The General Hospital Corp. | Method for augmenting vision in persons suffering from photoreceptor cell degeneration |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| JP2007527738A (ja) | 2003-11-05 | 2007-10-04 | ニューロヴィジョン， インコーポレイテッド | 視覚を改善するための方法および装置 |
| EP1919497B1 (en) | 2005-07-22 | 2020-02-12 | The Board of Trustees of the Leland Stanford Junior University | Light-activated cation channel and uses thereof |
| EP2019588A4 (en) | 2006-05-04 | 2010-11-24 | Univ Wayne State | RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN |
| WO2011140279A1 (en) * | 2010-05-04 | 2011-11-10 | Wayne State University | Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
| PL2614079T3 (pl) * | 2010-09-08 | 2016-01-29 | Max Planck Gesellschaft | Zmutowana kanałowa rodopsyna 2 |
| AU2013230112A1 (en) * | 2012-03-05 | 2014-09-25 | Wayne State University | Identification of channelrhodopsin-2 (Chop2) mutations and methods of use |
| KR101639859B1 (ko) * | 2014-03-06 | 2016-07-14 | 포항공과대학교 산학협력단 | 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법 |
-
2013
- 2013-03-05 AU AU2013230112A patent/AU2013230112A1/en not_active Abandoned
- 2013-03-05 KR KR1020147027985A patent/KR102137717B1/ko active Active
- 2013-03-05 PT PT13710253T patent/PT2822964T/pt unknown
- 2013-03-05 MX MX2014010664A patent/MX360085B/es active IP Right Grant
- 2013-03-05 CA CA2866405A patent/CA2866405A1/en active Pending
- 2013-03-05 ES ES13710253T patent/ES2703324T3/es active Active
- 2013-03-05 WO PCT/US2013/029171 patent/WO2013134295A1/en not_active Ceased
- 2013-03-05 HU HUE13710253A patent/HUE040487T2/hu unknown
- 2013-03-05 CN CN201380022635.5A patent/CN104334575A/zh active Pending
- 2013-03-05 PL PL13710253T patent/PL2822964T3/pl unknown
- 2013-03-05 US US14/383,211 patent/US10947281B2/en active Active
- 2013-03-05 EA EA201491643A patent/EA201491643A1/ru unknown
- 2013-03-05 NZ NZ629843A patent/NZ629843A/en unknown
- 2013-03-05 DK DK13710253.9T patent/DK2822964T3/en active
- 2013-03-05 JP JP2014561051A patent/JP6395611B2/ja active Active
- 2013-03-05 CN CN202010025519.0A patent/CN111378020A/zh active Pending
- 2013-03-05 EP EP13710253.9A patent/EP2822964B1/en active Active
-
2017
- 2017-10-06 AU AU2017239601A patent/AU2017239601B2/en active Active
-
2018
- 2018-04-23 JP JP2018082403A patent/JP2018134098A/ja not_active Withdrawn
-
2019
- 2019-07-01 JP JP2019123061A patent/JP2019193656A/ja active Pending
- 2019-08-14 AU AU2019216638A patent/AU2019216638B2/en active Active
-
2021
- 2021-03-15 US US17/202,064 patent/US20220033449A1/en not_active Abandoned
- 2021-10-07 AU AU2021245195A patent/AU2021245195B2/en active Active
-
2024
- 2024-04-18 US US18/639,381 patent/US20250066431A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510759A5 (https=) | ||
| US9421245B2 (en) | Targeted therapeutics | |
| ES2298378T3 (es) | Formulacion estable de glp-1 modificado. | |
| JP2013544494A5 (https=) | ||
| IL308807B1 (en) | Combination therapy for cancer treatment | |
| RU2013115454A (ru) | Мутантный канальный родопсин-2 | |
| BR112021009231A2 (pt) | vesículas extracelulares modificadas e usos das mesmas | |
| WO2017187272A8 (en) | Optogenetic visual restoration using chrimson | |
| CR20230026A (es) | Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532) | |
| PE20190660A1 (es) | Mutantes de la polimerasa de hbv | |
| ZA201705628B (en) | Methods and compositions for treating genetic eye diseases | |
| EP2470559A4 (en) | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM | |
| MX2008001865A (es) | Proteinas de fusion de albumina. | |
| RU2013143303A (ru) | FcγRIIb-СПЕЦИФИЧНОЕ Fc-АНТИТЕЛО | |
| AR102324A1 (es) | Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados | |
| NZ629843A (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use | |
| JP2019537437A5 (https=) | ||
| JP2018500390A5 (https=) | ||
| CN104066436B (zh) | 使用非糖基化载脂蛋白a‑iv治疗糖尿病的方法 | |
| JP2020518249A5 (https=) | ||
| CN114667298A (zh) | Siglec-9 ecd融合分子及其使用方法 | |
| JP2012102105A5 (https=) | ||
| CN117946281A (zh) | 长效神经生长因子多肽及其用途 | |
| WO2014145524A3 (en) | Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a | |
| WO2004019974A3 (en) | Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |